EUVIMEDEUVIMED entdecken
Open Access

Epidemiology and prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium in a tertiary hospital from Madrid, Spain

A Maldonado-Barrueco, M Rodríguez-Ayala, D Grandioso-Vas, P García-Clemente, G V Guedez-López, J García-Rodríguez, I Quiles-Melero

Revista Española de Quimioterapia · 2023

DOI: 10.37201/req/123.2022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista Española de Quimioterapia, 2023. Verfasst von A Maldonado-Barrueco und 6 weiteren Autor:innen. Beteiligte Einrichtung: Alfredo Maldonado-Barrueco, Clinical Microbiology and Parasitology Department. Hospital Universitario La Paz. Paseo de La Castellana 261, 28046 Madri…. Hauptthemen laut MEDLINE: Mycoplasma genitalium, Mycoplasma Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Mycoplasma genitalium causes persistent sexually transmitted infections. The aims of this study were to estimate the prevalence of resistances to macrolides and fluoroquinolones in M. genitalium and the sexually transmitted coinfections in patients at Hospital Universitario La Paz (Madrid, Spain). Material and methods. Patients attended between January and October 2021 were studied. Screening for sexually transmitted pathogens and detection of 23S rRNA and parC genes mutations were performed by real-time PCR (Allplex,SeegeneTM).

Results

A total of 1,518 females and 1,136 males were studied. The prevalence of M. genitalium was 2.1%. The macrolides resistance rate was 51.8%. The mutations found were A2059G, A2058T and A2058G. The rate of resistance to fluoroquinolones was 17.8% being the G248T mutation (S83I) the most frequent. Seven males had some sexual transmitted coinfection.

Conclusions

Although the percentage of M. genitalium infections is low, the high rate of resistance to macrolides makes it necessary to revise the protocols for diagnosis and empirical treatment of sexually transmitted infections. The use of fluoroquinolones is appropriate after screening of macrolide resistance profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycoplasma genitaliumMycoplasma InfectionsMaleFemaleHumansAnti-Bacterial AgentsFluoroquinolonesMacrolidesPrevalenceSpainTertiary Care CentersDrug Resistance, BacterialMutation

Stichwörter der Autor:innen

Mycoplasma genitaliumSTIazithromycincoinfectionfluoroquinolonesmacrolidesmoxifloxacinmutationresistance

Substanzen

Anti-Bacterial AgentsFluoroquinolonesMacrolides

Autor:innen und Institutionen

  • Alfredo Maldonado-Barrueco, Clinical Microbiology and Parasitology Department. Hospital Universitario La Paz. Paseo de La Castellana 261, 28046 Madrid, Spain. alfredo.maldonado@salud.madrid.org.

Zitieren

APA

Maldonado-Barrueco, A., Rodríguez-Ayala, M., Grandioso-Vas, D., García-Clemente, P., Guedez-López, G. V., García-Rodríguez, J., & Quiles-Melero, I. (2023). Epidemiology and prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium in a tertiary hospital from Madrid, Spain. Revista Española de Quimioterapia. https://doi.org/10.37201/req/123.2022

Vancouver

Maldonado-Barrueco A, Rodríguez-Ayala M, Grandioso-Vas D, García-Clemente P, Guedez-López GV, García-Rodríguez J, et al. Epidemiology and prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium in a tertiary hospital from Madrid, Spain. Revista Española de Quimioterapia. 2023. doi:10.37201/req/123.2022

BibTeX
@article{MaldonadoBarrueco2023,
  author = {Maldonado-Barrueco, A and Rodríguez-Ayala, M and Grandioso-Vas, D and García-Clemente, P and Guedez-López, G V and García-Rodríguez, J and Quiles-Melero, I},
  title = {Epidemiology and prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium in a tertiary hospital from Madrid, Spain},
  journal = {Revista Española de Quimioterapia},
  year = {2023},
  doi = {10.37201/req/123.2022}
}
Kostenlos starten →